📊 CBLL Key Takeaways
Is Ceribell, Inc. (CBLL) a Good Investment?
Ceribell exhibits classic pre-profitability medical device company characteristics: strong 36% revenue growth and exceptional 87% gross margins demonstrate product-market fit and pricing power, but severe operating losses (-78% margin) and negative cash burn (-$19.3M annually) signal company is far from profitability. With $45.3M cash and no debt, runway exists for 2+ years, making execution on cost control and revenue scaling the determining factor for viability.
Ceribell shows strong top-line momentum and exceptional gross margins, suggesting a differentiated product with real commercial traction. However, the business is still deeply unprofitable, with very negative operating margins and heavy cash burn, so the fundamental story depends on whether revenue growth can translate into meaningful operating leverage before cash consumption becomes a larger issue.
Ceribell, Inc. Key Strengths (CBLL)
- Strong 36.1% YoY revenue growth demonstrates market traction
- Exceptional 87.3% gross margin indicates healthy unit economics and pricing power
- Fortress balance sheet: $45.3M cash, zero debt, 10.4x current ratio provides multi-year runway
- Improving EPS (56.9% YoY) signals operating leverage improving despite losses
- Revenue growth of 36.1% YoY indicates strong demand and commercial expansion
- Gross margin of 87.9% suggests attractive unit economics and pricing power
- Very strong liquidity and no long-term debt provide balance-sheet flexibility while scaling
CBLL Stock Risks: Ceribell, Inc. Investment Risks
- Severe cash burn: -$19.3M operating cash flow against $26.5M revenue is unsustainable long-term
- Deep unprofitability: -78.3% operating margin and -74.5% net margin after reaching $26.5M scale suggests structural cost issues
- Negative free cash flow of -$19.4M means growth is funded by balance sheet depletion, not cash generation
- Medical device sector requires sustained R&D spend and regulatory compliance; gross margin compression or revenue slowdown would be critical
- Operating margin of -65.6% shows the cost structure remains far from sustainable
- Free cash flow of -$41.58M means the company is still consuming substantial cash
- Net losses remain large relative to revenue, creating execution risk if growth slows
Key Metrics to Watch
- Operating cash flow trajectory: must turn positive before cash reserves deplete
- Operating margin expansion: must show path to breakeven as revenue scales
- Cash runway: current $45.3M with -$19.3M burn rate critical; monitor quarterly burn rate
- Revenue growth sustainability: confirm 36% growth is not demand front-loading; monitor cohort retention
- Operating margin improvement versus revenue growth
- Free cash flow burn and ending cash balance
Ceribell, Inc. (CBLL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.44x current ratio provides a solid financial cushion.
CBLL Profit Margin, ROE & Profitability Analysis
CBLL vs Healthcare Sector: How Ceribell, Inc. Compares
How Ceribell, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ceribell, Inc. Stock Overvalued? CBLL Valuation Analysis 2026
Based on fundamental analysis, Ceribell, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ceribell, Inc. Balance Sheet: CBLL Debt, Cash & Liquidity
CBLL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ceribell, Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.39 indicates the company is currently unprofitable.
CBLL Revenue Growth, EPS Growth & YoY Performance
CBLL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.5M | -$12.8M | $-0.36 |
| Q3 2025 | $17.2M | -$8.5M | $-0.37 |
| Q2 2025 | $15.3M | -$8.5M | $-0.38 |
| Q1 2025 | $14.4M | -$8.5M | $-0.36 |
| Q3 2024 | $11.6M | -$6.2M | $-1.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ceribell, Inc. Dividends, Buybacks & Capital Allocation
CBLL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ceribell, Inc. (CIK: 0001861107)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBLL
What is the AI rating for CBLL?
Ceribell, Inc. (CBLL) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBLL's key strengths?
Claude: Strong 36.1% YoY revenue growth demonstrates market traction. Exceptional 87.3% gross margin indicates healthy unit economics and pricing power. ChatGPT: Revenue growth of 36.1% YoY indicates strong demand and commercial expansion. Gross margin of 87.9% suggests attractive unit economics and pricing power.
What are the risks of investing in CBLL?
Claude: Severe cash burn: -$19.3M operating cash flow against $26.5M revenue is unsustainable long-term. Deep unprofitability: -78.3% operating margin and -74.5% net margin after reaching $26.5M scale suggests structural cost issues. ChatGPT: Operating margin of -65.6% shows the cost structure remains far from sustainable. Free cash flow of -$41.58M means the company is still consuming substantial cash.
What is CBLL's revenue and growth?
Ceribell, Inc. reported revenue of $26.5M.
Does CBLL pay dividends?
Ceribell, Inc. does not currently pay dividends.
Where can I find CBLL SEC filings?
Official SEC filings for Ceribell, Inc. (CIK: 0001861107) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBLL's EPS?
Ceribell, Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CBLL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Ceribell, Inc. has a B grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CBLL stock overvalued or undervalued?
Valuation metrics for CBLL: ROE of -14.0% (sector avg: 15%), net margin of -74.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CBLL's AI grade for 2026?
Our dual AI analysis gives Ceribell, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CBLL's free cash flow?
Ceribell, Inc.'s operating cash flow is $-19.3M, with capital expenditures of $125.0K. FCF margin is -73.3%.
How does CBLL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -74.5% (avg: 12%), ROE -14.0% (avg: 15%), current ratio 10.44 (avg: 2).